Mpox disease severity reduced in intradermally MVA-BN vaccinated compared to unvaccinated patients in Sweden: a retrospective 2024-2025 observational case-series
Clicks: 1
ID: 315934
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #155 of 208 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Modified Vaccinia Ankara–Bavarian Nordic vaccination (MVA-BN) prevents mpox, whether offered subcutaneously or intradermally. Intradermal administration has been implemented as a dose-sparing strategy, but evidence on durability of protection and long-term clinical impact is limited. We evaluated mpox severity over time in a limited number of mpox cases following primary intradermal MVA-BN vaccination. Methods We conducted a retrospective case series of laboratory-confirmed mpox diagnosed between January 2024 and October 2025 at a major HIV and sexual health center in Stockholm, Sweden. Demographic and clinical data, vaccination history, and treatment outcomes were extracted from medical records. Disease severity was assessed using the validated Mpox Severity Score System. Results Seventy-nine patients were included (median age 40 years); 32 unvaccinated and 47 had prior vaccination with; smallpox vaccine (n=6), smallpox plus MVA-BN (n=11), or MVA-BN only (n=30). All MVA-BN doses were administered intradermally. Breakthrough infections occurred a median of 22 months after MVA-BN vaccination. Vaccinated individuals had significantly milder disease, with lower median severity score (5.0 vs. 8.0; p<0.0001), fewer lesions, more limited distribution, and less mucosal involvement. No MVA-BN vaccinated patient developed complications with bacterial superinfection (p=0.002), and analgesic requirements were reduced (p=0.004). Disease severity showed a modest inverse correlation with time since vaccination (r=−0.42, p=0.01). Similar attenuation was observed in vaccinated individuals with well-controlled HIV. Conclusions Dose-sparing intradermal MVA-BN vaccination is associated with sustained reduction in mpox severity for up to three years. Continued vaccination of high-risk populations is supported, while prospective studies are needed to clarify long-term protection and optimize vaccination strategies.
| Reference Key |
openalex_W7163594516
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Catharina Missailidis, Anna Mia Ekström, Finn Filén, Andreas Jacks, Katarina Widgren, Magnus Gisslén, Klara Sondén, Kari Johansen |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag337
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.